162 related articles for article (PubMed ID: 33092088)
1. Engineered Human Nanoferritin Bearing the Drug Genz-644282 for Cancer Therapy.
Falvo E; Arcovito A; Conti G; Cipolla G; Pitea M; Morea V; Damiani V; Sala G; Fracasso G; Ceci P
Pharmaceutics; 2020 Oct; 12(10):. PubMed ID: 33092088
[TBL] [Abstract][Full Text] [Related]
2. Widespread in vivo efficacy of The-0504: A conditionally-activatable nanoferritin for tumor-agnostic targeting of CD71-expressing cancers.
Fracasso G; Falvo E; Tisci G; Sala G; Colotti G; Cingarlini S; Tito C; Bibbo S; Frusteri C; Tremante E; Giordani E; Giacomini P; Ceci P
Heliyon; 2023 Oct; 9(10):e20770. PubMed ID: 37860543
[TBL] [Abstract][Full Text] [Related]
3. High activity and low toxicity of a novel CD71-targeting nanotherapeutic named The-0504 on preclinical models of several human aggressive tumors.
Falvo E; Damiani V; Conti G; Boschi F; Messana K; Giacomini P; Milella M; De Laurenzi V; Morea V; Sala G; Fracasso G; Ceci P
J Exp Clin Cancer Res; 2021 Feb; 40(1):63. PubMed ID: 33568214
[TBL] [Abstract][Full Text] [Related]
4. The presence of glutamate residues on the PAS sequence of the stimuli-sensitive nano-ferritin improves in vivo biodistribution and mitoxantrone encapsulation homogeneity.
Falvo E; Malagrinò F; Arcovito A; Fazi F; Colotti G; Tremante E; Di Micco P; Braca A; Opri R; Giuffrè A; Fracasso G; Ceci P
J Control Release; 2018 Apr; 275():177-185. PubMed ID: 29474961
[TBL] [Abstract][Full Text] [Related]
5. Mitoxantrone-Loaded Nanoferritin Slows Tumor Growth and Improves the Overall Survival Rate in a Subcutaneous Pancreatic Cancer Mouse Model.
Conti G; Pitea M; Ossanna R; Opri R; Tisci G; Falvo E; Innamorati G; Ghanem E; Sbarbati A; Ceci P; Fracasso G
Biomedicines; 2021 Nov; 9(11):. PubMed ID: 34829851
[TBL] [Abstract][Full Text] [Related]
6. Selective delivery of doxorubicin by novel stimuli-sensitive nano-ferritins overcomes tumor refractoriness.
Fracasso G; Falvo E; Colotti G; Fazi F; Ingegnere T; Amalfitano A; Doglietto GB; Alfieri S; Boffi A; Morea V; Conti G; Tremante E; Giacomini P; Arcovito A; Ceci P
J Control Release; 2016 Oct; 239():10-8. PubMed ID: 27524282
[TBL] [Abstract][Full Text] [Related]
7. Engineered Ferritin with Eu
Affatigato L; Sciortino A; Sancataldo G; Incocciati A; Piacentini R; Bonamore A; Cannas M; Messina F; Licciardi M; Militello V
Photochem Photobiol; 2023; 99(5):1218-1224. PubMed ID: 36484733
[TBL] [Abstract][Full Text] [Related]
8. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
9. Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatment.
Kurtzberg LS; Roth S; Krumbholz R; Crawford J; Bormann C; Dunham S; Yao M; Rouleau C; Bagley RG; Yu XJ; Wang F; Schmid SM; Lavoie EJ; Teicher BA
Clin Cancer Res; 2011 May; 17(9):2777-87. PubMed ID: 21415217
[TBL] [Abstract][Full Text] [Related]
10. Rubitecan: 9-NC, 9-Nitro-20(S)-camptothecin, 9-nitro-camptothecin, 9-nitrocamptothecin, RFS 2000, RFS2000.
Drugs R D; 2004; 5(5):305-11. PubMed ID: 15357630
[TBL] [Abstract][Full Text] [Related]
11. Camptothecin in sterically stabilized phospholipid micelles: a novel nanomedicine.
Koo OM; Rubinstein I; Onyuksel H
Nanomedicine; 2005 Mar; 1(1):77-84. PubMed ID: 17292061
[TBL] [Abstract][Full Text] [Related]
12. Engineered ferritin for lanthanide binding.
Calisti L; Trabuco MC; Boffi A; Testi C; Montemiglio LC; des Georges A; Benni I; Ilari A; Taciak B; Białasek M; Rygiel T; Król M; Baiocco P; Bonamore A
PLoS One; 2018; 13(8):e0201859. PubMed ID: 30102720
[TBL] [Abstract][Full Text] [Related]
13. Camptothecin-based nanodrug delivery systems.
Wen Y; Wang Y; Liu X; Zhang W; Xiong X; Han Z; Liang X
Cancer Biol Med; 2017 Nov; 14(4):363-370. PubMed ID: 29372102
[TBL] [Abstract][Full Text] [Related]
14. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells.
Jacob S; Aguado M; Fallik D; Praz F
Cancer Res; 2001 Sep; 61(17):6555-62. PubMed ID: 11522654
[TBL] [Abstract][Full Text] [Related]
15. Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independent mechanisms.
Coudray AM; Louvet C; Kornprobst M; Raymond E; André T; Tournigand C; Faivre S; De Gramont A; Larsen AK; Gespach C
Int J Oncol; 2005 Aug; 27(2):553-61. PubMed ID: 16010439
[TBL] [Abstract][Full Text] [Related]
16. Nano-Engineered Mesenchymal Stem Cells Increase Therapeutic Efficacy of Anticancer Drug Through True Active Tumor Targeting.
Layek B; Sadhukha T; Panyam J; Prabha S
Mol Cancer Ther; 2018 Jun; 17(6):1196-1206. PubMed ID: 29592881
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of 7-[2-(N-isopropylamino)ethyl]-(20S)-camptothecin, CKD602, as a potent DNA topoisomerase I inhibitor.
Lee JH; Lee JM; Kim JK; Ahn SK; Lee SJ; Kim MY; Jew SS; Park JG; Hong CI
Arch Pharm Res; 1998 Oct; 21(5):581-90. PubMed ID: 9875499
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
[TBL] [Abstract][Full Text] [Related]
19. Antibody-drug conjugates: targeting melanoma with cisplatin encapsulated in protein-cage nanoparticles based on human ferritin.
Falvo E; Tremante E; Fraioli R; Leonetti C; Zamparelli C; Boffi A; Morea V; Ceci P; Giacomini P
Nanoscale; 2013 Dec; 5(24):12278-85. PubMed ID: 24150593
[TBL] [Abstract][Full Text] [Related]
20. Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models.
Bobrov E; Skobeleva N; Restifo D; Beglyarova N; Cai KQ; Handorf E; Campbell K; Proia DA; Khazak V; Golemis EA; Astsaturov I
Oncotarget; 2017 Jan; 8(3):4399-4409. PubMed ID: 27779106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
